MENU
+Compare
BLUE
Stock ticker:
AS OF
May 30 closing price
Price
$4.97
Change
-$0.00 (-0.00%)
Capitalization
48.67M

BLUE bluebird bio Inc Forecast, Technical & Fundamental Analysis

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform... Show more

Industry: #Biotechnology
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BLUE with price predictions
Jun 27, 2025

Momentum Indicator for BLUE turns positive, indicating new upward trend

BLUE saw its Momentum Indicator move above the 0 level on June 12, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Aroon Indicator entered an Uptrend today. In of 100 cases where BLUE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BLUE turned negative on June 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.174) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). BLUE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.464) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BLUE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of next generation products based on the transformative potential of gene therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
455 Grand Union Boulevard
Phone
+1 339 499-9300
Employees
323
Web
https://www.bluebirdbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X108385.5700001057.875000
+0.99%
Bitcoin cryptocurrency
SPY614.913.04
+0.50%
SPDR® S&P 500® ETF
GME23.590.04
+0.17%
GameStop Corp
AAPL201.00N/A
N/A
Apple
TSLA323.63-2.15
-0.66%
Tesla

BLUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BLUE has been loosely correlated with ARGX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if BLUE jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLUE
1D Price
Change %
BLUE100%
N/A
ARGX - BLUE
40%
Loosely correlated
+0.02%
MTVA - BLUE
37%
Loosely correlated
-7.35%
CYCN - BLUE
35%
Loosely correlated
+6.86%
CTMX - BLUE
33%
Loosely correlated
-2.60%
TARA - BLUE
32%
Poorly correlated
-3.69%
More